- Connecticut Innovations announces $7.2 million in investments in 26 companies in the second quarter of its 2021 fiscal year
- Bioscience, health care information, and IT are principal recipients
- Investments help leverage $156 million in outside capital
Summary by Dirk Langeveld
Twenty-six companies received $7.2 million in funding from Connecticut Innovations during the second quarter of its 2021 fiscal year, the organization recently announced.
CI, which serves as Connecticut’s strategic venture capital arm and provides financing and other support services to innovative startups, said the investments occurred for the quarter ending Dec. 31, 2020. The investments helped secure an additional $156 million in outside capital.
The bulk of the funding, $4.3 million, went toward bioscience and health care information technology companies. Another $2.4 million was invested in IT companies.
The largest investments went to:
- Artizan Biosciences, a New Haven biotech company with a mission to “restore lives disrupted by inflammatory disease through innovation and advancement of microbiota-targeted therapies”
- DiA Imaging Analysis, which includes a location in Rocky Hill and leverages artificial intelligence to improve the use and analysis of ultrasound images
- IsoPlexis, a Branford biotechnology company specializing in detection systems for cancer and other diseases
- Payveris, a Cromwell-based intelligent digital payment platform
